Research into pharmacological GLUT5 inhibition with 2,5-AM revealed its efficacy in suppressing fructose-driven proliferation and mobility in AML under glucose restriction and its synergistic effects with the chemotherapy drug Ara-C, enhancing treatment potential (Chen et al. 2016) (Fig. 3). Here, SLC2A5 is linked to acute myeloid leukemia.